- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06524544
En studie som sammenligner kombinasjonen av Pembrolizumab og Sacituzumab Govitecan versus Sacituzumab Govitecan alene i behandling av avansert urotelkreft
En fase III randomisert studie av Pembrolizumab i kombinasjon med Sacituzumab Govitecan vs Sacituzumab Govitecan alene ved anti-PD(L)1-resistent avansert urotelkreft
This phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan-hziy to standard of care in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Sacituzumab govitecan-hziy is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug called govitecan-hziy. Sacituzumab attaches to TROP2 positive tumor cells in a targeted way and delivers govitecan-hziy to kill them. The usual treatment approach is treatment with chemotherapy such as cisplatin, carboplatin, gemcitabine, docetaxel or paclitaxel. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Giving pembrolizumab and sacituzumab govitecan-hziy may be more effective than usual care of carboplatin or cisplatin with gemcitabine, docetaxel or paclitaxel in treating patients with locally advanced or metastatic urothelial cancer.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
- Legemiddel: Carboplatin
- Legemiddel: Paclitaxel
- Legemiddel: Cisplatin
- Legemiddel: Docetaxel
- Fremgangsmåte: Biospecimen Collection
- Fremgangsmåte: Computed Tomography
- Fremgangsmåte: Magnetic Resonance Imaging
- Annen: Questionnaire Administration
- Biologisk: Pembrolizumab
- Legemiddel: Gemcitabine
- Biologisk: Sacituzumab Govitecan
Detaljert beskrivelse
PRIMARY OBJECTIVE:
I. To compare overall survival (OS) between the therapy of physician choice (TPC) arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
SECONDARY OBJECTIVES:
I. To compare the progression free survival (PFS) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
II. To evaluate overall response rate (ORR) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
III. To evaluate clinical benefit rate (complete response [CR]/partial response [PR] /stable disease [SD]) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
IV. To evaluate duration of response (DoR) between the TPC arm and the Sacituzumab govitecan-hziy + pembrolizumab arm.
V. To evaluate toxicity of the Sacituzumab govitecan-hziy + pembrolizumab arm using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).
EXPLORATORY HEALTH RELATED QUALITY OF LIFE (HRQOL) OBJECTIVES:
I. To compare HRQOL, as assessed by the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18) summary score between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm at 6 months.
II. To compare HRQOL change from baseline, as assessed by the FBISI-18 summary score, for patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm at baseline, 3, 6, and 12 months.
III. To compare the change in patient-reported fatigue from baseline and across 3, 6, and 12 months as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) summary score; change from baseline will be compared between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
IV. To compare quality-adjusted survival (overall survival x health utility score assessed by the European Quality of Life Five Dimension Five Level [EQ-5D-5L]) between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
V. To compare time to HRQOL deterioration in global HRQOL, as measured by the FBISI-18 disease-related physical symptom subscale (FBISI-18 disease-related symptoms (DRS) in the physical emotional domains [DRS-P]), between patients on the TPC arm versus the Sacituzumab govitecan-hziy + pembrolizumab arm.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive TPC with carboplatin or cisplatin intravenously (IV) on day 1 and gemcitabine IV on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may alternately receive TPC with docetaxel IV on day 1 of each cycle or paclitaxel IV on either day 1 or days 1, 8, and 15 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the study.
ARM B: Patients receive sacituzumab govitecan-hziy IV over 1-3 hours on days 1 and 8 and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 35 cycles or for 2 years of pembrolizumab in the absence of disease progression or unacceptable toxicity. Cycles of sacituzumab govitecan-hziy repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, and CT or MRI throughout the study.
After completion of study treatment, patients are followed up at 30 days then once a year for 5 years from the date of randomization.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85004
- Rekruttering
- Cancer Center at Saint Joseph's
-
Hovedetterforsker:
- Loretta J. Nastoupil
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-post: ResearchInstituteInquiries@CommonSpirit.org
-
-
California
-
Irvine, California, Forente stater, 92612
- Rekruttering
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 877-827-8839
- E-post: ucstudy@uci.edu
-
Hovedetterforsker:
- Nataliya Mar
-
Orange, California, Forente stater, 92868
- Rekruttering
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 877-827-8839
- E-post: ucstudy@uci.edu
-
Hovedetterforsker:
- Nataliya Mar
-
-
Florida
-
Gainesville, Florida, Forente stater, 32610
- Rekruttering
- UF Health Cancer Institute - Gainesville
-
Hovedetterforsker:
- Daniel V. Araujo
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 352-273-8010
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory University Hospital/Winship Cancer Institute
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 404-778-1868
-
Hovedetterforsker:
- Jacqueline T. Brown
-
Atlanta, Georgia, Forente stater, 30308
- Rekruttering
- Emory University Hospital Midtown
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 888-946-7447
-
Hovedetterforsker:
- Jacqueline T. Brown
-
Atlanta, Georgia, Forente stater, 30342
- Rekruttering
- Emory Saint Joseph's Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 404-851-7115
-
Hovedetterforsker:
- Jacqueline T. Brown
-
-
Idaho
-
Coeur d'Alene, Idaho, Forente stater, 83814
- Rekruttering
- Kootenai Health - Coeur d'Alene
-
Hovedetterforsker:
- John M. Schallenkamp
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-post: mccinfo@mtcancer.org
-
Post Falls, Idaho, Forente stater, 83854
- Rekruttering
- Kootenai Clinic Cancer Services - Post Falls
-
Hovedetterforsker:
- John M. Schallenkamp
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-post: mccinfo@mtcancer.org
-
Sandpoint, Idaho, Forente stater, 83864
- Rekruttering
- Kootenai Clinic Cancer Services - Sandpoint
-
Hovedetterforsker:
- John M. Schallenkamp
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-post: mccinfo@mtcancer.org
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60612
- Rekruttering
- University of Illinois
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 312-355-3046
-
Hovedetterforsker:
- Karine Tawagi
-
Danville, Illinois, Forente stater, 61832
- Rekruttering
- Carle at The Riverfront
-
Hovedetterforsker:
- Priyank P. Patel
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-post: Research@Carle.com
-
Decatur, Illinois, Forente stater, 62526
- Rekruttering
- Cancer Care Specialists of Illinois - Decatur
-
Hovedetterforsker:
- Bryan A. Faller
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-post: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Forente stater, 62526
- Rekruttering
- Decatur Memorial Hospital
-
Hovedetterforsker:
- Bryan A. Faller
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-post: morganthaler.jodi@mhsil.com
-
Effingham, Illinois, Forente stater, 62401
- Rekruttering
- Carle Physician Group-Effingham
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-post: Research@carle.com
-
Hovedetterforsker:
- Priyank P. Patel
-
Effingham, Illinois, Forente stater, 62401
- Rekruttering
- Crossroads Cancer Center
-
Hovedetterforsker:
- Bryan A. Faller
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-post: morganthaler.jodi@mhsil.com
-
Mattoon, Illinois, Forente stater, 61938
- Rekruttering
- Carle Physician Group-Mattoon/Charleston
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-post: Research@carle.com
-
Hovedetterforsker:
- Priyank P. Patel
-
Normal, Illinois, Forente stater, 61761
- Rekruttering
- Carle BroMenn Medical Center
-
Hovedetterforsker:
- Priyank P. Patel
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-post: Research@Carle.com
-
Normal, Illinois, Forente stater, 61761
- Rekruttering
- Carle Cancer Institute Normal
-
Hovedetterforsker:
- Priyank P. Patel
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-post: Research@Carle.com
-
O'Fallon, Illinois, Forente stater, 62269
- Rekruttering
- Cancer Care Center of O'Fallon
-
Hovedetterforsker:
- Bryan A. Faller
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-post: morganthaler.jodi@mhsil.com
-
O'Fallon, Illinois, Forente stater, 62269
- Rekruttering
- HSHS Saint Elizabeth's Hospital
-
Hovedetterforsker:
- Bryan A. Faller
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-post: morganthaler.jodi@mhsil.com
-
Shiloh, Illinois, Forente stater, 62269
- Rekruttering
- Memorial Hospital East
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 314-747-9912
- E-post: dschwab@wustl.edu
-
Hovedetterforsker:
- Melissa A. Reimers
-
Springfield, Illinois, Forente stater, 62702
- Rekruttering
- Southern Illinois University School of Medicine
-
Hovedetterforsker:
- Bryan A. Faller
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 217-545-7929
-
Springfield, Illinois, Forente stater, 62702
- Rekruttering
- Springfield Clinic
-
Hovedetterforsker:
- Bryan A. Faller
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-444-7541
-
Springfield, Illinois, Forente stater, 62781
- Rekruttering
- Springfield Memorial Hospital
-
Hovedetterforsker:
- Bryan A. Faller
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 217-528-7541
- E-post: pallante.beth@mhsil.com
-
Urbana, Illinois, Forente stater, 61801
- Rekruttering
- Carle Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-post: Research@carle.com
-
Hovedetterforsker:
- Priyank P. Patel
-
-
Iowa
-
Ames, Iowa, Forente stater, 50010
- Rekruttering
- Mary Greeley Medical Center
-
Hovedetterforsker:
- Joseph J. Merchant
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 515-956-4132
-
Ames, Iowa, Forente stater, 50010
- Rekruttering
- McFarland Clinic - Ames
-
Hovedetterforsker:
- Joseph J. Merchant
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 515-239-4734
- E-post: ksoder@mcfarlandclinic.com
-
Boone, Iowa, Forente stater, 50036
- Suspendert
- McFarland Clinic - Boone
-
Cedar Rapids, Iowa, Forente stater, 52403
- Rekruttering
- Mercy Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 319-365-4673
-
Hovedetterforsker:
- Deborah W. Wilbur
-
Cedar Rapids, Iowa, Forente stater, 52403
- Rekruttering
- Oncology Associates at Mercy Medical Center
-
Hovedetterforsker:
- Deborah W. Wilbur
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 319-363-2690
-
Fort Dodge, Iowa, Forente stater, 50501
- Rekruttering
- McFarland Clinic - Trinity Cancer Center
-
Hovedetterforsker:
- Joseph J. Merchant
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 515-956-4132
-
Jefferson, Iowa, Forente stater, 50129
- Suspendert
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Forente stater, 50158
- Rekruttering
- McFarland Clinic - Marshalltown
-
Hovedetterforsker:
- Joseph J. Merchant
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 515-956-4132
-
-
Kansas
-
Hays, Kansas, Forente stater, 67601
- Rekruttering
- HaysMed
-
Hovedetterforsker:
- Saqib Abbasi
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 785-623-5774
-
Kansas City, Kansas, Forente stater, 66160
- Rekruttering
- University of Kansas Cancer Center
-
Hovedetterforsker:
- Saqib Abbasi
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-post: KUCC_Navigation@kumc.edu
-
Lawrence, Kansas, Forente stater, 66044
- Rekruttering
- Lawrence Memorial Hospital
-
Hovedetterforsker:
- Saqib Abbasi
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 785-505-2800
- E-post: Stephanie.Norris@LMH.ORG
-
Olathe, Kansas, Forente stater, 66061
- Rekruttering
- The University of Kansas Cancer Center - Olathe
-
Hovedetterforsker:
- Saqib Abbasi
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 913-588-1569
- E-post: OlatheCCResearch@kumc.edu
-
Overland Park, Kansas, Forente stater, 66210
- Rekruttering
- University of Kansas Cancer Center-Overland Park
-
Hovedetterforsker:
- Saqib Abbasi
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-post: KUCC_Navigation@kumc.edu
-
Salina, Kansas, Forente stater, 67401
- Rekruttering
- Salina Regional Health Center
-
Hovedetterforsker:
- Saqib Abbasi
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 785-452-7038
- E-post: mleepers@srhc.com
-
Topeka, Kansas, Forente stater, 66606
- Rekruttering
- University of Kansas Health System Saint Francis Campus
-
Hovedetterforsker:
- Saqib Abbasi
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 785-295-8000
-
Westwood, Kansas, Forente stater, 66205
- Rekruttering
- University of Kansas Hospital-Westwood Cancer Center
-
Hovedetterforsker:
- Saqib Abbasi
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-post: KUCC_Navigation@kumc.edu
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40202
- Rekruttering
- The James Graham Brown Cancer Center at University of Louisville
-
Hovedetterforsker:
- Rohit Kumar
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 502-562-3429
-
Louisville, Kentucky, Forente stater, 40245
- Rekruttering
- UofL Health Medical Center Northeast
-
Hovedetterforsker:
- Rohit Kumar
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 502-852-2755
- E-post: ctoinfo@louisville.edu
-
-
Louisiana
-
Baton Rouge, Louisiana, Forente stater, 70809
- Rekruttering
- Louisiana Hematology Oncology Associates LLC
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 225-215-1353
- E-post: clinicalresearch@marybird.com
-
Hovedetterforsker:
- Scott E. Delacroix
-
Metairie, Louisiana, Forente stater, 70002
- Rekruttering
- Mary Bird Perkins Cancer Center - Metairie
-
Hovedetterforsker:
- Scott E. Delacroix
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 504-584-6990
-
-
Massachusetts
-
Worcester, Massachusetts, Forente stater, 01655
- Rekruttering
- UMass Memorial Medical Center - University Campus
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 508-856-3216
- E-post: cancer.research@umassmed.edu
-
Hovedetterforsker:
- Kriti Mittal
-
-
Michigan
-
Brighton, Michigan, Forente stater, 48114
- Rekruttering
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-post: MCRCwebsitecontactform@stjoeshealth.org
-
Hovedetterforsker:
- Houssam Y. Hariri
-
Canton, Michigan, Forente stater, 48188
- Rekruttering
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-post: MCRCwebsitecontactform@stjoeshealth.org
-
Hovedetterforsker:
- Houssam Y. Hariri
-
Chelsea, Michigan, Forente stater, 48118
- Rekruttering
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-post: MCRCwebsitecontactform@stjoeshealth.org
-
Hovedetterforsker:
- Houssam Y. Hariri
-
Lansing, Michigan, Forente stater, 48912
- Rekruttering
- University of Michigan Health - Sparrow Lansing
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 517-364-3712
- E-post: harsha.trivedi@umhsparrow.org
-
Hovedetterforsker:
- Houssam Y. Hariri
-
Livonia, Michigan, Forente stater, 48154
- Rekruttering
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-post: MCRCwebsitecontactform@stjoeshealth.org
-
Hovedetterforsker:
- Houssam Y. Hariri
-
Pontiac, Michigan, Forente stater, 48341
- Rekruttering
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-post: MCRCwebsitecontactform@stjoeshealth.org
-
Hovedetterforsker:
- Houssam Y. Hariri
-
Ypsilanti, Michigan, Forente stater, 48197
- Rekruttering
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-post: MCRCwebsitecontactform@stjoeshealth.org
-
Hovedetterforsker:
- Houssam Y. Hariri
-
-
Minnesota
-
Brainerd, Minnesota, Forente stater, 56401
- Rekruttering
- Essentia Health Saint Joseph's Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-post: CancerTrials@EssentiaHealth.org
-
Hovedetterforsker:
- Bret E. Friday
-
Coon Rapids, Minnesota, Forente stater, 55433
- Rekruttering
- Mercy Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-post: mmcorc@healthpartners.com
-
Hovedetterforsker:
- David M. King
-
Deer River, Minnesota, Forente stater, 56636
- Rekruttering
- Essentia Health - Deer River Clinic
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-post: CancerTrials@EssentiaHealth.org
-
Hovedetterforsker:
- Bret E. Friday
-
Duluth, Minnesota, Forente stater, 55805
- Rekruttering
- Essentia Health Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-post: CancerTrials@EssentiaHealth.org
-
Hovedetterforsker:
- Bret E. Friday
-
Edina, Minnesota, Forente stater, 55435
- Rekruttering
- Fairview Southdale Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-post: mmcorc@healthpartners.com
-
Hovedetterforsker:
- David M. King
-
Edina, Minnesota, Forente stater, 55435
- Rekruttering
- Minnesota Oncology - Edina
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-post: mmcorc@healthpartners.com
-
Hovedetterforsker:
- David M. King
-
Hibbing, Minnesota, Forente stater, 55746
- Rekruttering
- Essentia Health Hibbing Clinic
-
Hovedetterforsker:
- Bret E. Friday
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 218-786-3308
-
Marshall, Minnesota, Forente stater, 56258
- Rekruttering
- Avera Cancer Institute at Marshall
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 605-322-3095
- E-post: OncRegulatory@avera.org
-
Hovedetterforsker:
- Ryan A. Vaca
-
Minneapolis, Minnesota, Forente stater, 55407
- Rekruttering
- Abbott-Northwestern Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-post: mmcorc@healthpartners.com
-
Hovedetterforsker:
- David M. King
-
Saint Louis Park, Minnesota, Forente stater, 55416
- Rekruttering
- Park Nicollet Clinic - Saint Louis Park
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-post: mmcorc@healthpartners.com
-
Hovedetterforsker:
- David M. King
-
Saint Paul, Minnesota, Forente stater, 55101
- Rekruttering
- Regions Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-post: mmcorc@healthpartners.com
-
Hovedetterforsker:
- David M. King
-
Saint Paul, Minnesota, Forente stater, 55102
- Rekruttering
- United Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-post: mmcorc@healthpartners.com
-
Hovedetterforsker:
- David M. King
-
Sandstone, Minnesota, Forente stater, 55072
- Rekruttering
- Essentia Health Sandstone
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-post: CancerTrials@EssentiaHealth.org
-
Hovedetterforsker:
- Bret E. Friday
-
Virginia, Minnesota, Forente stater, 55792
- Rekruttering
- Essentia Health Virginia Clinic
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-post: CancerTrials@EssentiaHealth.org
-
Hovedetterforsker:
- Bret E. Friday
-
-
Missouri
-
Cape Girardeau, Missouri, Forente stater, 63703
- Rekruttering
- Saint Francis Medical Center
-
Hovedetterforsker:
- Bryan A. Faller
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 573-334-2230
- E-post: sfmc@sfmc.net
-
City of Saint Peters, Missouri, Forente stater, 63376
- Rekruttering
- Siteman Cancer Center at Saint Peters Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-post: info@siteman.wustl.edu
-
Hovedetterforsker:
- Melissa A. Reimers
-
Creve Coeur, Missouri, Forente stater, 63141
- Rekruttering
- Siteman Cancer Center at West County Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-post: info@siteman.wustl.edu
-
Hovedetterforsker:
- Melissa A. Reimers
-
Farmington, Missouri, Forente stater, 63640
- Rekruttering
- Parkland Health Center - Farmington
-
Hovedetterforsker:
- Bryan A. Faller
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Kansas City, Missouri, Forente stater, 64154
- Rekruttering
- University of Kansas Cancer Center - North
-
Hovedetterforsker:
- Saqib Abbasi
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-post: KUCC_Navigation@kumc.edu
-
Kansas City, Missouri, Forente stater, 64108
- Rekruttering
- University Health Truman Medical Center
-
Hovedetterforsker:
- Saqib Abbasi
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 816-404-4375
-
Kansas City, Missouri, Forente stater, 64116
- Rekruttering
- University of Kansas Cancer Center - Briarcliff
-
Hovedetterforsker:
- Saqib Abbasi
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 913-588-3671
-
Lee's Summit, Missouri, Forente stater, 64064
- Rekruttering
- University of Kansas Cancer Center - Lee's Summit
-
Hovedetterforsker:
- Saqib Abbasi
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 913-588-3671
- E-post: KUCC_Navigation@kumc.edu
-
Sainte Genevieve, Missouri, Forente stater, 63670
- Rekruttering
- Sainte Genevieve County Memorial Hospital
-
Hovedetterforsker:
- Bryan A. Faller
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
St Louis, Missouri, Forente stater, 63110
- Rekruttering
- Washington University School of Medicine
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-post: info@siteman.wustl.edu
-
Hovedetterforsker:
- Melissa A. Reimers
-
St Louis, Missouri, Forente stater, 63129
- Rekruttering
- Siteman Cancer Center-South County
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-post: info@siteman.wustl.edu
-
Hovedetterforsker:
- Melissa A. Reimers
-
St Louis, Missouri, Forente stater, 63136
- Rekruttering
- Siteman Cancer Center at Christian Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-post: info@siteman.wustl.edu
-
Hovedetterforsker:
- Melissa A. Reimers
-
St Louis, Missouri, Forente stater, 63131
- Rekruttering
- Missouri Baptist Medical Center
-
Hovedetterforsker:
- Bryan A. Faller
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Sullivan, Missouri, Forente stater, 63080
- Rekruttering
- Missouri Baptist Sullivan Hospital
-
Hovedetterforsker:
- Bryan A. Faller
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
-
Montana
-
Anaconda, Montana, Forente stater, 59711
- Rekruttering
- Community Hospital of Anaconda
-
Hovedetterforsker:
- John M. Schallenkamp
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-post: mccinfo@mtcancer.org
-
Billings, Montana, Forente stater, 59101
- Rekruttering
- Billings Clinic Cancer Center
-
Hovedetterforsker:
- John M. Schallenkamp
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-996-2663
- E-post: research@billingsclinic.org
-
Bozeman, Montana, Forente stater, 59715
- Rekruttering
- Bozeman Health Deaconess Hospital
-
Hovedetterforsker:
- John M. Schallenkamp
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-post: mccinfo@mtcancer.org
-
Great Falls, Montana, Forente stater, 59405
- Rekruttering
- Benefis Sletten Cancer Institute
-
Hovedetterforsker:
- John M. Schallenkamp
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-post: mccinfo@mtcancer.org
-
Kalispell, Montana, Forente stater, 59901
- Rekruttering
- Logan Health Medical Center
-
Hovedetterforsker:
- John M. Schallenkamp
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-post: mccinfo@mtcancer.org
-
Missoula, Montana, Forente stater, 59804
- Rekruttering
- Community Medical Center
-
Hovedetterforsker:
- John M. Schallenkamp
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-post: mccinfo@mtcancer.org
-
-
New Hampshire
-
Lebanon, New Hampshire, Forente stater, 03756
- Rekruttering
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-post: cancer.research.nurse@dartmouth.edu
-
Hovedetterforsker:
- Jacob B. Reibel
-
-
New Jersey
-
Livingston, New Jersey, Forente stater, 07039
- Rekruttering
- Cooperman Barnabas Medical Center
-
Hovedetterforsker:
- Biren Saraiya
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 973-322-5200
-
Long Branch, New Jersey, Forente stater, 07740
- Rekruttering
- Monmouth Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 732-923-6564
- E-post: mary.danish@rwjbh.org
-
Hovedetterforsker:
- Biren Saraiya
-
New Brunswick, New Jersey, Forente stater, 08903
- Rekruttering
- Rutgers Cancer Institute of New Jersey
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 732-235-7356
-
Hovedetterforsker:
- Biren Saraiya
-
Newark, New Jersey, Forente stater, 07101
- Rekruttering
- Rutgers New Jersey Medical School
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 732-235-7356
-
Hovedetterforsker:
- Biren Saraiya
-
Somerville, New Jersey, Forente stater, 08876
- Rekruttering
- Robert Wood Johnson University Hospital Somerset
-
Hovedetterforsker:
- Biren Saraiya
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 908-685-2481
- E-post: Siby.Varughese@rwjbh.org
-
Toms River, New Jersey, Forente stater, 08755
- Rekruttering
- Community Medical Center
-
Hovedetterforsker:
- Biren Saraiya
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 732-557-8294
- E-post: Lennette.Gonzales@rwjbh.org
-
-
New York
-
Buffalo, New York, Forente stater, 14263
- Rekruttering
- Roswell Park Cancer Institute
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-post: askroswell@roswellpark.org
-
Hovedetterforsker:
- Ellis G. Levine
-
Stony Brook, New York, Forente stater, 11794
- Rekruttering
- Stony Brook University Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-862-2215
-
Hovedetterforsker:
- Judy Huang
-
Williamsville, New York, Forente stater, 14221
- Rekruttering
- Roswell Park Amherst Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-post: askroswell@roswellpark.org
-
Hovedetterforsker:
- Ellis G. Levine
-
-
North Carolina
-
Hendersonville, North Carolina, Forente stater, 28791
- Rekruttering
- Margaret R Pardee Memorial Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 828-696-4716
- E-post: pardeecancerresearch@unchealth.unc.edu
-
Hovedetterforsker:
- John K. Hill
-
-
North Dakota
-
Fargo, North Dakota, Forente stater, 58103
- Rekruttering
- Essentia Health Cancer Center-South University Clinic
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-post: CancerTrials@EssentiaHealth.org
-
Hovedetterforsker:
- Bret E. Friday
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- Ohio State University Comprehensive Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-293-5066
- E-post: Jamesline@osumc.edu
-
Hovedetterforsker:
- Yuanquan Yang
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- Rekruttering
- University of Oklahoma Health Sciences Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-post: ou-clinical-trials@ouhsc.edu
-
Hovedetterforsker:
- Adanma Anji Ayanambakkam Attanathi
-
-
Pennsylvania
-
Danville, Pennsylvania, Forente stater, 17822
- Rekruttering
- Geisinger Medical Center
-
Hovedetterforsker:
- Sorab Gupta
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 570-271-5251
- E-post: cancerresearch@geisinger.edu
-
Dickson City, Pennsylvania, Forente stater, 18519
- Rekruttering
- Geisinger Cancer Center Dickson City
-
Hovedetterforsker:
- Sorab Gupta
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 877-204-6081
- E-post: cancerresearch@geisinger.edu
-
Erie, Pennsylvania, Forente stater, 16505
- Rekruttering
- UPMC Hillman Cancer Center Erie
-
Hovedetterforsker:
- Leonard J. Appleman
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 412-864-7716
- E-post: ClinicalResearchServices@upmc.edu
-
Erie, Pennsylvania, Forente stater, 16544
- Rekruttering
- Saint Vincent Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 814-452-5000
-
Hovedetterforsker:
- Alexander Helfand
-
Greensburg, Pennsylvania, Forente stater, 15601
- Rekruttering
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 724-838-1900
-
Hovedetterforsker:
- Leonard J. Appleman
-
Harrisburg, Pennsylvania, Forente stater, 17109
- Rekruttering
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 717-724-6765
- E-post: klitchfield@PINNACLEHEALTH.org
-
Hovedetterforsker:
- Leonard J. Appleman
-
Hershey, Pennsylvania, Forente stater, 17033-0850
- Rekruttering
- Penn State Milton S Hershey Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 717-531-3779
- E-post: CTO@hmc.psu.edu
-
Hovedetterforsker:
- Monika Joshi
-
Indiana, Pennsylvania, Forente stater, 15701
- Rekruttering
- IRMC Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 412-389-5208
- E-post: haneydl@upmc.edu
-
Hovedetterforsker:
- Leonard J. Appleman
-
Jefferson Hills, Pennsylvania, Forente stater, 15025
- Rekruttering
- Jefferson Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 412-359-3043
- E-post: ddefazio@wpahs.org
-
Hovedetterforsker:
- Alexander Helfand
-
Lewisburg, Pennsylvania, Forente stater, 17837
- Rekruttering
- Geisinger Medical Oncology-Lewisburg
-
Hovedetterforsker:
- Sorab Gupta
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 570-523-9200
- E-post: cancerresearch@geisinger.edu
-
Mechanicsburg, Pennsylvania, Forente stater, 17050
- Rekruttering
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 412-389-5208
- E-post: haneydl@upmc.edu
-
Hovedetterforsker:
- Leonard J. Appleman
-
Monroeville, Pennsylvania, Forente stater, 15146
- Rekruttering
- Forbes Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 412-858-7746
-
Hovedetterforsker:
- Alexander Helfand
-
Monroeville, Pennsylvania, Forente stater, 15146
- Rekruttering
- UPMC Hillman Cancer Center - Monroeville
-
Hovedetterforsker:
- Leonard J. Appleman
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 412-864-7716
- E-post: ClinicalResearchServices@upmc.edu
-
Natrona Heights, Pennsylvania, Forente stater, 15065
- Rekruttering
- Allegheny Valley Hospital
-
Ta kontakt med:
- Site Public Contact
- E-post: Dawnmarie.DeFazio@ahn.org
-
Hovedetterforsker:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- Rekruttering
- West Penn Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 412-578-5000
-
Hovedetterforsker:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, Forente stater, 15215
- Rekruttering
- UPMC-Saint Margaret
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 412-784-4900
-
Hovedetterforsker:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Forente stater, 15237
- Rekruttering
- UPMC-Passavant Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 412-367-6454
-
Hovedetterforsker:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Forente stater, 15212
- Rekruttering
- Allegheny General Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 877-284-2000
-
Hovedetterforsker:
- Alexander Helfand
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- Rekruttering
- UPMC Hillman Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 412-647-8073
-
Hovedetterforsker:
- Leonard J. Appleman
-
Seneca, Pennsylvania, Forente stater, 16346
- Rekruttering
- UPMC Cancer Center at UPMC Northwest
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 814-676-7900
-
Hovedetterforsker:
- Leonard J. Appleman
-
Uniontown, Pennsylvania, Forente stater, 15401
- Rekruttering
- UPMC Cancer Center-Uniontown
-
Ta kontakt med:
- Site Public Contact
- E-post: ecog.rss@jimmy.harvard.edu
-
Hovedetterforsker:
- Leonard J. Appleman
-
Washington, Pennsylvania, Forente stater, 15301
- Rekruttering
- UPMC Cancer Center-Washington
-
Ta kontakt med:
- Site Public Contact
- E-post: ecog.rss@jimmy.harvard.edu
-
Hovedetterforsker:
- Leonard J. Appleman
-
West Reading, Pennsylvania, Forente stater, 19611
- Rekruttering
- Reading Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 610-988-9323
-
Hovedetterforsker:
- Terrence P. Cescon
-
Wexford, Pennsylvania, Forente stater, 15090
- Rekruttering
- Wexford Health and Wellness Pavilion
-
Ta kontakt med:
- Site Public Contact
- E-post: Dawnmarie.DeFazio@ahn.org
-
Hovedetterforsker:
- Alexander Helfand
-
Wilkes-Barre, Pennsylvania, Forente stater, 18711
- Rekruttering
- Geisinger Wyoming Valley/Henry Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 570-271-5251
- E-post: HemonCCTrials@geisinger.edu
-
Hovedetterforsker:
- Sorab Gupta
-
-
South Dakota
-
Aberdeen, South Dakota, Forente stater, 57401
- Rekruttering
- Avera Cancer Institute-Aberdeen
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 605-622-8700
- E-post: oncregulatory@avera.org
-
Hovedetterforsker:
- Ryan A. Vaca
-
Mitchell, South Dakota, Forente stater, 57301
- Rekruttering
- Avera Cancer Institute - Mitchell
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 605-322-3096
- E-post: OncRegulatory@avera.org
-
Hovedetterforsker:
- Ryan A. Vaca
-
Pierre, South Dakota, Forente stater, 57501
- Rekruttering
- Avera Cancer Institute at Pierre
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 605-322-3095
- E-post: OncRegulatory@avera.org
-
Hovedetterforsker:
- Ryan A. Vaca
-
Sioux Falls, South Dakota, Forente stater, 57105
- Rekruttering
- Avera Cancer Institute
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 605-322-3095
- E-post: OncRegulatory@avera.org
-
Hovedetterforsker:
- Ryan A. Vaca
-
Yankton, South Dakota, Forente stater, 57078
- Rekruttering
- Avera Cancer Institute at Yankton
-
Hovedetterforsker:
- Ryan A. Vaca
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 605-655-1800
- E-post: OncRegulatory@avera.org
-
-
Texas
-
Baytown, Texas, Forente stater, 77521
- Rekruttering
- Houston Methodist San Jacinto Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-post: ctsucontact@westat.com
-
Hovedetterforsker:
- Patrick E. Prath
-
Cypress, Texas, Forente stater, 77429
- Rekruttering
- Houston Methodist Cypress Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 346-356-1413
- E-post: irb@houstonmethodist.org
-
Hovedetterforsker:
- Patrick E. Prath
-
Dallas, Texas, Forente stater, 75390
- Rekruttering
- UT Southwestern/Simmons Cancer Center-Dallas
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-post: canceranswerline@UTSouthwestern.edu
-
Hovedetterforsker:
- Suzanne M. Cole
-
Dallas, Texas, Forente stater, 75235
- Rekruttering
- Parkland Memorial Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 214-590-5582
- E-post: canceranswerline@UTSouthwestern.edu
-
Hovedetterforsker:
- Suzanne M. Cole
-
Dallas, Texas, Forente stater, 75237
- Rekruttering
- UT Southwestern Simmons Cancer Center - RedBird
-
Hovedetterforsker:
- Suzanne M. Cole
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-post: canceranswerline@utsouthwestern.edu
-
Fort Worth, Texas, Forente stater, 76104
- Rekruttering
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-post: canceranswerline@UTSouthwestern.edu
-
Hovedetterforsker:
- Suzanne M. Cole
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Houston Methodist Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 713-790-2700
-
Hovedetterforsker:
- Patrick E. Prath
-
Houston, Texas, Forente stater, 77070
- Rekruttering
- Methodist Willowbrook Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-post: ctsucontact@westat.com
-
Hovedetterforsker:
- Patrick E. Prath
-
Houston, Texas, Forente stater, 77094
- Rekruttering
- Houston Methodist West Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 832-522-2873
-
Hovedetterforsker:
- Patrick E. Prath
-
Nassau Bay, Texas, Forente stater, 77058
- Rekruttering
- Houston Methodist Saint John Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-post: ctsucontact@westat.com
-
Hovedetterforsker:
- Patrick E. Prath
-
Richardson, Texas, Forente stater, 75080
- Rekruttering
- UT Southwestern Clinical Center at Richardson/Plano
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 972-669-7044
- E-post: Suzanne.cole@utsouthwestern.edu
-
Hovedetterforsker:
- Suzanne M. Cole
-
Sugar Land, Texas, Forente stater, 77479
- Rekruttering
- Houston Methodist Sugar Land Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 281-242-2873
-
Hovedetterforsker:
- Patrick E. Prath
-
The Woodlands, Texas, Forente stater, 77385
- Rekruttering
- Houston Methodist The Woodlands Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 713-790-2700
- E-post: hmthewoodlands@houstonmethodist.org
-
Hovedetterforsker:
- Patrick E. Prath
-
-
Vermont
-
Berlin Corners, Vermont, Forente stater, 05602
- Rekruttering
- Central Vermont Medical Center/National Life Cancer Treatment
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 802-225-5400
-
Hovedetterforsker:
- Rahul Anil
-
Burlington, Vermont, Forente stater, 05401
- Rekruttering
- University of Vermont Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 802-656-4101
- E-post: rpo@uvm.edu
-
Hovedetterforsker:
- Rahul Anil
-
Burlington, Vermont, Forente stater, 05405
- Rekruttering
- University of Vermont and State Agricultural College
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 802-656-8990
- E-post: rpo@uvm.edu
-
Hovedetterforsker:
- Rahul Anil
-
Saint Johnsbury, Vermont, Forente stater, 05819
- Rekruttering
- Dartmouth Cancer Center - North
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-post: cancer.research.nurse@hitchcock.org
-
Hovedetterforsker:
- Jacob B. Reibel
-
-
Virginia
-
Fredericksburg, Virginia, Forente stater, 22408
- Rekruttering
- Hematology Oncology Associates of Fredericksburg Inc
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 540-371-0079
- E-post: cvaughn@hoafredericksburg.com
-
Hovedetterforsker:
- Asit K. Paul
-
Richmond, Virginia, Forente stater, 23229
- Rekruttering
- Virginia Cancer Institute
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 804-287-3000
- E-post: smoore@vacancer.com
-
Hovedetterforsker:
- Asit K. Paul
-
Richmond, Virginia, Forente stater, 23235
- Rekruttering
- VCU Massey Cancer Center at Stony Point
-
Ta kontakt med:
- Site Public Contact
- E-post: ctoclinops@vcu.edu
-
Hovedetterforsker:
- Asit K. Paul
-
Richmond, Virginia, Forente stater, 23298
- Rekruttering
- VCU Massey Comprehensive Cancer Center
-
Hovedetterforsker:
- Asit K. Paul
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 804-628-6430
- E-post: CTOclinops@vcu.edu
-
-
Washington
-
Bellevue, Washington, Forente stater, 98004
- Rekruttering
- FHCC Overlake
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 425-454-2148
-
Hovedetterforsker:
- Mikhail G. Perlov
-
Kirkland, Washington, Forente stater, 98034
- Rekruttering
- FHCC at EvergreenHealth
-
Hovedetterforsker:
- Prakash Varadarajan
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 425-899-6000
-
Seattle, Washington, Forente stater, 98195
- Rekruttering
- University of Washington Medical Center - Montlake
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-804-8824
-
Hovedetterforsker:
- Petros Grivas
-
Seattle, Washington, Forente stater, 98109
- Rekruttering
- Fred Hutchinson Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 800-804-8824
-
Hovedetterforsker:
- Petros Grivas
-
Seattle, Washington, Forente stater, 98133
- Rekruttering
- FHCC at Northwest Hospital
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 206-606-5800
-
Hovedetterforsker:
- Nellowe Candelario
-
-
West Virginia
-
Charleston, West Virginia, Forente stater, 25304
- Rekruttering
- Vandalia Health/CAMC Institute for Academic Medicine
-
Hovedetterforsker:
- Kok Hoe Chan
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 304-388-9944
- E-post: CAMCClinicalTrials@vandaliahealth.org
-
-
Wisconsin
-
Appleton, Wisconsin, Forente stater, 54911
- Rekruttering
- ThedaCare Regional Cancer Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 920-364-3604
- E-post: ResearchDept@thedacare.org
-
Hovedetterforsker:
- Joyce Philip
-
Ashland, Wisconsin, Forente stater, 54806
- Rekruttering
- Duluth Clinic Ashland
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 218-786-3308
- E-post: CancerTrials@EssentiaHealth.org
-
Hovedetterforsker:
- Bret E. Friday
-
La Crosse, Wisconsin, Forente stater, 54601
- Rekruttering
- Gundersen Lutheran Medical Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 608-775-2385
- E-post: cancerctr@gundersenhealth.org
-
Hovedetterforsker:
- Kurt Oettel
-
New Richmond, Wisconsin, Forente stater, 54017
- Rekruttering
- Cancer Center of Western Wisconsin
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-post: mmcorc@healthpartners.com
-
Hovedetterforsker:
- David M. King
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Patient must be ≥ 18 years of age
-
Patient must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
-
Patient must have locally advanced (unresectable and/or not amenable to curative intent therapy) or metastatic urothelial cancer
-
Patient must have histologically (or based on urine cytology) proven conventional urothelial carcinoma (UC) of any urinary tract origin [any histologic subtype except neuroendocrine (small or large cell)] are permitted so long as tumors include ≥ 1% conventional urothelial histology). NOTE: Pure non-urothelial histology is excluded
-
Patient must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Baseline imaging must be obtained ≤ 35 days prior to randomization
-
Patient must have the following prior treatment(s). Patient must have had progression on or after the immediate prior anti-cancer therapy
-
Patient must have had prior exposure to anti-PD(L)1 therapy [anti -PD(L)1 monotherapy or as a combination regimen in any disease/therapy setting for UC]. Patients must have received at least 1 dose of anti-PD(L)1 therapy
- NOTE: Anti-PD(L)1 therapy does not need to be the most recent therapy received prior to enrollment on this protocol
- NOTE: Patient must not have had progression within 12 weeks of starting their first anti-PD(L) 1 therapy, even if anti-PD-(L)1 treatment was given in more than one lines of therapy
-
Patient must have had ≥ 1 line of systemic therapy given in the advanced/metastatic disease setting, except for patients who had received anti-PD(L)1 + enfortumab vedotin in the localized disease setting (e.g., neoadjuvant and/or adjuvant) and had cancer progression within 12 months from the last systemic therapy dose
-
For tumors with known FGFR3+ susceptible alteration (for FGFR inhibitor), patients must have received a prior FGFR inhibitor unless contraindicated per physician discretion
-
Patient must have received prior enfortumab vedotin or any other Nectin-4 directed therapy or other MMAE-containing therapy in any disease/therapy setting unless contraindicated per physician
-
Patient must have had no prior exposure to Sacituzumab govitecan-hziy or other TROP-2 directed therapies or antibody-drug conjugate that contains topo-isomerase I inhibitor, e.g. trastuzumab deruxtecan
-
Patient must have Bellmunt score of 0-2. The Bellmunt score assesses a patient's risk and is calculated based on ECOG PS, hemoglobin level and presence of liver metastases
-
Patient must not have history of grade 3-4 immune-related adverse events on prior anti-PD1/L1, except for endocrinopathies on adequate hormone therapy repletion and/or clinically insignificant laboratory abnormalities
-
Patient must have recovered (i.e., ≤ grade 1) from clinically significant AEs due to previously administered systemic therapy agent, except for endocrinopathies on adequate hormone therapy repletion
-
NOTE: Patients with ≤ grade 2 neuropathy, any grade of alopecia, or any grade of non-clinically significant laboratory abnormality are exceptions to this criterion and are allowed in this trial.
-
Examples of non-clinically significant laboratory abnormalities include, but are not limited to:
- Lymphopenia or monopenia
- Lymphocytosis or monocytosis
- Increase in amylase or lipase with no clinical correlation
- Any other abnormal laboratory findings that have no clinical relevance per the treating investigator.
-
NOTE: If patient has undergone major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to randomization
-
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). Patient must not nurse infants while on protocol treatment and for 4 months after the last dose of protocol treatment
-
Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Patients of childbearing potential must continue contraceptive method(s) or abstain for 6 months after the last dose of protocol treatment. Patients with partners who could become pregnant should use effective contraception during therapy and for 3 months after the last dose of protocol treatment
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Absolute neutrophil count (ANC) ≥ 1,500/uL (obtained ≤ 14 days prior to randomization)
-
Platelets ≥ 100,000/uL (obtained ≤ 14 days prior to randomization)
-
Albumin ≥ 3 g/dL (obtained ≤ 14 days prior to randomization)
-
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 14 days prior to randomization)
-
Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 3 × institutional ULN or ≤ 5.0 x institutional ULN if known liver metastases (obtained ≤ 14 days prior to randomization)
-
Creatinine clearance (CrCl) ≥ 30 mL/min (obtained ≤ 14 days prior to randomization) NOTE: CrCl is estimated using the Cockcroft-Gault formula (or can be measured by 24-hour urine collection if needed)
-
Hemoglobin (Hb) ≥ 8.5 g/dl (obtained ≤ 14 days prior to randomization)
-
Patient must not have a known genetic UGT1A1 *28/*28 or *6/*6 homozygous variant genotype. Patients with homozygous variant types are considered poor metabolizers and are at higher risk for severe adverse events when compared to wild-type. Patients with heterozygous UGT1A1 variants (i.e. *1/*28 or *1/*6) are eligible and should be counseled accordingly and be very closely monitored if randomized to the sacituzumab govitecan arm
- NOTE: If a patient's UGT1A1 status is unknown, they are eligible to enroll (the study does not require this test as part of screening)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with history of hepatitis C virus (HCV) infection must have been treated and considered cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and are not using steroids > 10 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to randomization
-
Patients with prior or concurrent malignancy that is not considered clinically significant and whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (at the discretion of the treating physician) are eligible
-
Patient must not be on systemic immunosuppressive medication, including steroids (if doses exceed the equivalent of prednisone 10 mg daily). Short courses of steroids, e.g. "burst", which are discontinued prior to randomization are acceptable. Patients on inhaled, intranasal, intra-articular and/or topical steroids are eligible
-
Patient must be English or Spanish speaking to be eligible for the HRQOL component of the study.
- NOTE: Sites cannot translate the associated HRQOL forms
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Arm I (TPC chemotherapy)
Patients receive TPC with carboplatin or cisplatin IV on day 1 and gemcitabine IV on days 1 and 8 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may alternately receive TPC with docetaxel IV on day 1 of each cycle or paclitaxel IV on either day 1 or days 1, 8, and 15 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection and CT or MRI throughout the study. |
Given IV
Andre navn:
Given IV
Andre navn:
Given IV
Andre navn:
Given IV
Andre navn:
Undergo blood sample collection
Andre navn:
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Ancillary studies Given IV
Andre navn:
|
|
Eksperimentell: Arm II (pembrolizumab, sacituzumab govitecan-hziy)
Patients receive pembrolizumab IV over 30 minutes on day 1 and sacituzumab govitecan-hziy IV over 1-3 hours on days 1 and 8 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, and CT or MRI throughout the study. |
Undergo blood sample collection
Andre navn:
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Ancillary studies Given IV
Andre navn:
Given IV
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall survival (OS)
Tidsramme: From randomization to death due to any cause, assessed up to 5 years
|
OS will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The hazard ratio (HR) will be estimated, and a 95% confidence interval (CI) will be reported. |
From randomization to death due to any cause, assessed up to 5 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free survival (PFS)
Tidsramme: From randomization to the earlier progression or death due to any cause, assessed up to 5 years
|
PFS will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. PFS will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The HR will be estimated, and a 95% CI will be reported. |
From randomization to the earlier progression or death due to any cause, assessed up to 5 years
|
|
Overall response rate (ORR)
Tidsramme: Up to 5 years
|
ORR will be assessed among patients who received at least one dose of protocol therapy using RECIST v 1.1 criteria. ORR will be defined as the number of patients with complete response (CR) and partial response (PR) divided by the number of treated patients. ORR will be calculated based on the definition by arm and will be reported with 95% CI. |
Up to 5 years
|
|
Clinical benefit rate (CBR)
Tidsramme: Up to 5 years
|
CBR will be defined as CR, PR, or stable disease per RECIST v 1.1. CBR will be calculated based on the definition by arm and will be reported with 95% CI. |
Up to 5 years
|
|
Duration of response (DOR)
Tidsramme: From the first occurrence of a documented objective response to disease progression or death, whichever occurs first, assessed up to 5 years
|
DOR will be assessed by RECIST v1.1. DOR will be characterized with the method of Kaplan-Meier and will be compared between the two treatment arms using stratified log-rank test. The HR will be estimated, and a 95% CI will be reported. |
From the first occurrence of a documented objective response to disease progression or death, whichever occurs first, assessed up to 5 years
|
|
Incidence of adverse events (AEs)
Tidsramme: Up to 30 days after last dose of study drug
|
AEs will be graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The percentage of patients with toxicities will be tabulated. The 90% CI for the true probability of observing toxicity of ≥ grade 4 on a given arm will be no wider than 12.3 %. The probability of observing ≥ 1 toxicity on a given arm with a true rate of 1% is 85.5%. |
Up to 30 days after last dose of study drug
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18) summary score
Tidsramme: At baseline and at 3, 6 and 12 months
|
Change in patient reported FBISI-18 score will be compared between arms using a two-sample t-test. Assessment time will be considered as a continuous variable if there is a linear trend in quality of life (QOL) assessments over time or a set of dummy variables if a non-linear trend exists. Patient demographics and disease characteristics will be adjusted in the mixed effect model. A t-test will be performed to explore change of FBISI-18 summary score. |
At baseline and at 3, 6 and 12 months
|
|
Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) summary score
Tidsramme: At baseline and at 3, 6 and 12 months
|
Change in patient reported FACIT-F score will be compared between arms using a two-sample t-test. Mixed effect models will be constructed to estimate the time profile of FACIT-F in the two arms and to evaluate treatment-by-time interactions. Assessment time will be considered as a continuous variable if there is a linear trend in QOL assessments over time or a set of dummy variables if a non-linear trend exists. Patient demographics and disease characteristics will be adjusted in the mixed effect model. |
At baseline and at 3, 6 and 12 months
|
|
Change in quality-adjusted survival (assessed by the European Quality of Life Five Dimension Five Level scale [EQ-5D-5L]).
Tidsramme: At baseline and at 3, 6 and 12 months
|
Change in patient reported EQ-5D-5L will be compared between the arms using a two-sample t-test. Quality-adjusted survival (assessed by the EQ-5D-5L), will be analyzed with quality-adjusted time without symptoms or toxicity. |
At baseline and at 3, 6 and 12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Monika Joshi, ECOG-ACRIN Cancer Research Group
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer
- Neoplasmer etter histologisk type
- Neoplasmer, kjertel og epitel
- Karsinom
- Karsinom, overgangscelle
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Undersøkelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Hydrokarboner
- Cycloparaffins
- Hydrokarboner, alicyklisk
- Hydrokarboner, syklisk
- Terpener
- Uorganiske kjemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Koordinasjonskomplekser
- Taxoider
- Cyclodecanes
- Diterpenes
- Deoxycytidine
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Elementer
- Metaller
- Helsevesenets økonomi og organisasjoner
- Kjemisteknikker, analytisk
- Spektrumanalyse
- Metaller, tunge
- Platinumforbindelser
- Overgangselementer
- Økonomi
- Docetaxel
- Gemcitabin
- Karboplatin
- Paclitaxel
- Cisplatin
- 1,2-diaminocykloheksanplatina II sitrat
- Prøvehåndtering
- pembrolizumab
- Magnetisk resonansspektroskopi
- Platinum
- Sacituzumab Govitecan
- Skatter
Andre studie-ID-numre
- NCI-2024-06208
- U10CA180820 (U.S. NIH-stipend/kontrakt)
- NCI-2024-06208 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- EA8231 (Annen identifikator: CTEP)
- EA8231 (Annen identifikator: ECOG-ACRIN Cancer Research Group)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .